PharmaTelevision - Roche:Genentech Integration Latest: Exclusive interview on PharmaTelevision

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Roche:Genentech Integration Latest: Exclusive interview on PharmaTelevision

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

PharmaTelevision announced today that it is to broadcast an exclusive interview with Dan Zabrowski, Global Head, Pharma Partnering, Roche Pharmaceuticals Division and Joe McCracken, Vice President, Business Development, Genentech, on the Roche:Genentech integration, on June 4th 2009.

The interview on the business TV show "PharmaVentures Business Review" reveals the new structure and position for Genentech in the Roche organisation and how companies wishing to partner with Roche or Genentech can do so in the future. The interview also discusses broader issues such as the future position of Genentech and its role moving forwards.

Dr Fintan Walton, CEO of PharmaVentures, who also presents the PharmaTelevision shows and interviewed both Zabrowski and McCracken, said: "This exclusive interview provides insight into the operations of one of the world's largest pharmaceutical companies. We are delighted that Roche used PharmaTelevision to communicate its integration strategy and how its implementation is progressing".

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The Process of integration and the strategy of implementation.

Fintan Walton:

Hello and welcome we are here at bio 2009 at the annual convention here in Atlanta. We are here to record a series of programs with leading pharmaceutical and biotechnology companies to talk about the both their vision and what they are doing to build their organizations in tough economic times. Hello and welcome to PharmaVentures business review here at Bio in Atlanta. On this show I have Dan Zabrowski who is the head of pharma partnering at Roche and with him Joe McCrackenwho is vice president of business development at Genentech welcome to the show both of you.

Dan Zabrowski:

Thank you for having us.

Joseph McCracken:

Thank you for having us .

Fintan Walton:

The reason why both of you are sitting here talking to me as two, would have been two separate entities today you are all part of one organization and I want to talk about that organization that new Roche which integrates the Genentech side and I want us to talk about that but also want to get to the some of the important component parts which is how partnering is going to be done in the future and how that relates to basically how drugs are going to be bought into the new organization. So Danif I could start with you Rocheobviously was a majority share holder in Genentech in the past and now it 's a 100% owned part of Rocheand the integration has started and could you tell us a little bit about how in general that integration is taking place what sort of picture can we see for Rocheand Genentech as we go forward particularly here in the United States?

Dan Zabrowski:

Well the integration actually is going at full speed. We have an integration steering committee made up of members of Rocheand Genentech who meet on a weekly basis to address our questions and proposals that are presented by each of the work streams. I would say our planning is on track to be completed by the middle of the year and then at that point I think Severin Schwan will come out and communicate the results of that plan and what the expectations are for the new company going forward.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Joseph McCracken

Vice President, Business Development, Genentech

Dr Dan Zabrowski is a member of the Roche Pharma Executive Committee and has been Global Head of Pharma Partnering since July 2007, based at Roche 's headquarters in Basel, Switzerland. Since joining Rochein 1993, he has held a number of leadership roles including Global Head of Pharma Development Operations and Global Head of Pharma Development Regulatory. Prior to that he was Executive Director, Drug Regulatory Affairs at Syntex, which was integrated into the Roche Group in 1994. Dan was awarded his PhD in organic chemistry from Indiana University, USA, having gained his first degree in chemistry from St Louis University, USA. Dr Joseph McCracken was appointed as Vice President, Business Development at Genentech in August 2000. Before that, he served as Vice President of Technology Licensing and Alliances at Aventis Pharmaceuticals in Bridgewater, New Jersey. Previously, he worked as Vice President, Worldwide Business and Technology Development, at Rh�ne-Poulenc Rorer. Josephalso worked at Genentech earlier in his career, when he served in many capacities, culminating in the position of Representative Director, Genentech Limited Tokyo. He holds a Bachelor of Science degree in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from Ohio State University.

Roche

Roche As a research-focused healthcare company, Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver significant benefits to patients and healthcare professionals � from early detection and prevention of diseases to diagnosis, treatment, and treatment monitoring. Roche employs over about 80,000 people and sells it's products in over 150 countries. The company was founded on October 1st, 1896. The founder, Fritz Hoffmann-La Roche, was among the first to recognize that the industrial manufacture of standardized medicines would be a major advance in the fight against disease. From the very beginning, Roche 's visionary founder focused his company on innovation and on establishing an international presence. Today Roche ranks among the world 's leading healthcare companies and has two strong core businesses: diagnostics and pharmaceuticals. Genentech Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human geneticinformation to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world 's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions, more than 100 projects in the pipeline and a long term plan for growth. In March 2009 Roche acquired the remaining publicly held outstanding common stock in Genentech.